Through the proposed license agreement, Taisho would grant exclusive development and commercialization rights outside Japan for TS-032 to Pfizer. If the license agreement is signed, Taisho will receive from Pfizer an initial payment of U.S. $22 million. Taisho will also receive milestone payments tied to progress of development, as well as royalties and milestone payments tied to sales if TS-032 is approved by regulatory authorities and launched.
TS-032 is a novel mGluR (metabotropic glutamate receptor) agonist that may offer a new treatment option for central nervous system disorders. Although the characteristics of mGluR are still only partly understood, mGluR is believed to play a role in the transmission of glutamate and other substances in the brain. Abnormalities in the neurotransmission through mGluR may be one cause for symptoms related to schizophrenia as well as other CNS disorders. Data show that mGluR agonists, such as TS-032, offer potential as new treatments for schizophrenia.
About Taisho Pharmaceutical Co., Ltd.
Taisho is the leading company in OTC drugs in Japan. At the same time, it is steadily strengthening its prescription drug research and development by improving its internal research capacity in that field. These efforts have seen it make progress with several original projects, including the research into TS-032 as a new drug candidate. Through ongoing proprietary R&D and active collaboration with Japanese and foreign companies, Taisho is determined to bolster its prescription pharmaceuticals business. For more information, visit www.taisho.co.jp.
About Pfizer Inc
Pfizer Inc, founded in 1849, is dedicated to better health and greater access to health care for people and their valued animals. Every day, approximately 90,000 colleagues in more than 150 countries work to discover, develop, manufacture and deliver quality, safe and effective prescription medicines to patients. For more information, visit www.pfizer.com.